Sakurabonsai: protocol design of a novel, prospective study to explore clinical, imaging, and biomarker outcomes in patients with aqp4-igg-seropositive neuromyelitis optica spectrum disorder receiving open-label satralizumab

HIGHLIGHTS

• who: Jeffrey L. Bennett from the Heinrich Heine University of Du00fcsseldorf, Germany have published the research work: SAkuraBONSAI: Protocol design of a novel, prospective study to explore clinical, imaging, and biomarker outcomes in patients with AQP4-IgG-seropositive neuromyelitis optica spectrum disorder receiving open-label satralizumab, in the Journal: (JOURNAL)
• what: The authors report the study design of SAkuraBONSAI, a prospective study to assess comprehensive longitudinal, clinical, imaging, and blood and cerebrospinal fluid (CSF) mechanistic biomarker assessments in NMOSD. The aim of this study is to describe the efficacy of satralizumab in patients with AQP4 . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.